Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.51 |
| ▸ | LNPEP | Q9UIQ6 | 1/20 | 0.47 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.46 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.46 |
| ▸ | CTSS | P25774 | 10/20 | 0.45 |
| ▸ | CTSK | P43235 | 9/20 | 0.45 |
| ▸ | CTSB | P07858 | 4/20 | 0.45 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7439577 | 0.89 | KLK5 (0.54) | KLK5ITGA4ITGB7CTSSCTSK | |
| SCHEMBL24065192 | 0.89 | LNPEP (0.56) | KLK5LNPEPCTSSCTSKCTSB | |
| SCHEMBL30958049 | 0.87 | KLK5 (0.52) | KLK5ITGA4ITGB7CTSSCTSK | |
| SCHEMBL10042354 | 0.87 | KLK5 (0.52) | KLK5ITGA4ITGB7CTSSCTSK | |
| SCHEMBL30958037 | 0.87 | KLK5 (0.52) | KLK5ITGA4ITGB7CTSSCTSK | |
| SCHEMBL24476991 | 0.87 | KLK5 (0.52) | KLK5ITGA4ITGB7CTSSCTSK | |
| SCHEMBL5786508 | 0.87 | KLK5 (0.52) | KLK5ITGA4ITGB7CTSSCTSK | |
| SCHEMBL26699643 | 0.86 | KLK5 (0.51) | KLK5LNPEPCTSSCTSKCTSB | |
| SCHEMBL26699639 | 0.86 | KLK5 (0.51) | KLK5LNPEPCTSSCTSKCTSB | |
| SCHEMBL24853653 | 0.85 | KLK5 (0.50) | KLK5LNPEPCTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | KLK5 4761/4885LNPEP 2884/4885ITGA4 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.